SAB Biotherapeutics (SABS) Stock Statistics & Valuation Metrics

SAB Biotherapeutics has a market cap or net worth of $16.54M. The enterprise value is $4.41B.

SAB Biotherapeutics has 9,291,697 shares outstanding. The number of shares has decreased by -2.65% in one year.

SAB Biotherapeutics’s return on equity (ROE) is -1.31 and return on invested capital (ROIC) is -115.89%.

The current PE Ratio of SAB Biotherapeutics is -1.03. SAB Biotherapeutics’s PEG ratio is 0.00.

In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.10M in profits. Earnings per share was -3.68.

In the last 12 months, operating cash flow was -31.41M and capital expenditures -208.18K, giving a free cash flow of -31.62M billion.

SAB Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SAB Biotherapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

SAB Biotherapeutics as a current ratio of 2.98, with Debt / Equity ratio of -331.27%

In the past 12 months, SAB Biotherapeutics has paid 0.00 in taxes.

SAB Biotherapeutics EV to EBITDA ratio is -1.06, with an EV/FCF ratio of -0.89.

SAB Biotherapeutics has $12.85M in cash and marketable securities with $6.78M in debt, giving a net cash position of -$6.07M billion.

Gross margin is 100.00%, with operating margin of -3244.87%, and net profit margin of -2579.03%.

The average price target for SAB Biotherapeutics is $12.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy